ALYREF and neoplasm: Since the NSUN2/ALYREF/m5C‐PFAS oncogenic cascade is an important trigger of RB, our study provides a novel targeted m5C reprogramming therapeutic strategy, which may potentially be an efficient anti‐tumour therapy approach.